

# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for 6 Months of Age and Older



The table below provides guidance for COVID-19 vaccination schedules based on age and medical condition. Scheduling considerations include:

- Administer the appropriate vaccine product based on the recipient's age and the product's age indications.
- COVID-19 vaccines may be administered on the same day as other vaccines.
- Doses administered at any time after the intervals outlined below are valid.

Detailed information can be found in CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, see: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html)

**Table 1. Immunization Schedule for Children 6 Months through 17 Years of Age**

Type	Product*	Recipient Age	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses <sup>†‡</sup>	Doses	Interval Between Doses <sup>†‡</sup>
mRNA vaccine	Moderna (Blue vial cap with magenta-bordered label)	6 months through 5 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks <sup>†</sup>	Dose 1 to 2	At least 4 weeks
					Dose 2 to 3	At least 4 weeks
	Moderna (Blue vial cap with purple-bordered label)	6 through 11 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks <sup>†</sup>	Dose 1 to 2	At least 4 weeks
					Dose 2 to 3	At least 4 weeks
	Moderna (Red vial cap with blue-bordered label)	12 through 17 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks <sup>†</sup>	Dose 1 to 2	At least 4 weeks
					Dose 2 to 3	At least 4 weeks
	Pfizer-BioNTech (Maroon vial cap with maroon-bordered label)	6 months through 4 years	Total number: 3 doses		Total number: 3 doses	
			Dose 1 to 2	At least 3–8 weeks <sup>†</sup>	Dose 1 to 2	At least 3 weeks
			Doses 2 and 3	At least 8 weeks	Dose 2 to 3	At least 8 weeks
Pfizer-BioNTech (Orange vial cap with orange-bordered label)	5 through 11 years	Total number: 3 doses		Total number: 4 doses		
		Dose 1 to 2	At least 3–8 weeks <sup>†</sup>	Dose 1 to 2	At least 3 weeks	
		Dose 2 to 3	At least 5 months	Dose 2 to 3	At least 4 weeks	
		Dose 3 to 4	At least 3 months			
Pfizer-BioNTech (Purple vial cap with a purple-bordered label or gray vial cap with gray-bordered label)	12 years through 17 years	Total number: 3 doses		Total number: 5 doses		
		Dose 1 to 2	At least 3–8 weeks <sup>†</sup>	Dose 1 to 2	At least 3 weeks	
		Dose 2 to 3	At least 5 months	Dose 2 to 3	At least 4 weeks	
				Dose 3 to 4	At least 3 months	
		Dose 4 to 5	At least 4 months			

\* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose. Any COVID-19 vaccine product (age appropriate) may be administered for a booster dose. It does not need to be the same product used for the primary series.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

# COVID-19 Vaccine

Interim COVID-19 Immunization Schedule  
for 6 Months of Age and Older



**Table 2. Immunization Schedule for Persons 18 Years of Age**

Type	Product*	Recipient Age	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses <sup>†</sup>	Doses	Interval Between Doses <sup>††</sup>
mRNA vaccine	Moderna (Red vial cap with a blue-bordered label)	18 years and older	Total number: 3 or 4 doses		Total number: 5 doses	
			Dose 1 to 2	At least 4–8 weeks <sup>‡</sup>	Dose 1 to 2	At least 4 weeks
			Dose 2 to 3	At least 5 months	Dose 2 to 3	At least 4 weeks
			Dose 3 to 4	At least 4 months for persons ages 50 years and older	Dose 3 to 4	At least 3 months
	Dose 4 to 5	At least 4 months				
	Pfizer-BioNTech (Purple vial cap with a purple-bordered label or gray vial cap with gray-bordered label)	18 years and older	Total number: 3 or 4 doses		Total number: 5 doses	
			Dose 1 to 2	At least 3-8 weeks <sup>‡</sup>	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 5 months	Dose 2 to 3	At least 4 weeks
			Dose 3 to 4	At least 4 months for persons ages 50 years and older	Dose 3 to 4	At least 3 months
	Dose 4 to 5	At least 4 months				
Viral vector vaccine	Janssen <sup>§</sup>	18 years and older	Total number: 2 or 3 doses		Total number: 4 doses	
			Dose 1 to 2	At least 8 weeks	Dose 1 to 2	At least 4 weeks (mRNA vaccine) <sup>¶</sup>
			Dose 2 to 3	At least 4 months for persons ages 50 years and older (mRNA vaccine) <sup>**</sup>	Dose 2 to 3	At least 8 weeks <sup>§</sup>
Dose 3 to 4	At least 4 months (mRNA vaccine) <sup>¶</sup>					

\* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose. Any COVID-19 vaccine product (age appropriate) may be administered for a booster dose. It does not need to be the same product used for the primary series. An mRNA COVID-19 vaccine is preferred.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

§ Age-appropriate mRNA COVID-19 vaccines are preferred over the Janssen COVID-19 Vaccine for all vaccine doses for all vaccine-eligible people 18 years of age and older. Janssen COVID-19 vaccine should only be used in limited situations. See: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html)

¶ mRNA vaccine must be used.

\*\* People ages 18–49 years: Those who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the Janssen booster dose.

# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for 6 Months of Age and Older




### Special Situations When Vaccinating Children

1. Vaccine from Different Manufacturers Given to a Child 6 months through 4 Years of Age: COVID-19 vaccine from the same manufacturer should be used for the primary series. If a different manufacturer is inadvertently administered, follow the guidance below:

- If a dose of the age-appropriate product from BOTH Moderna and Pfizer-BioNTech COVID-19 is inadvertently given, count both doses if the recommended interval between doses has been met.
  - Complete the series following the Pfizer-BioNTech 3-dose schedule using an age-appropriate vaccine from either manufacturer. See examples.
  - Repeating doses is not recommended.
- This guidance applies to:
  - All eligible children, including those who are moderately or severely immunocompromised.
  - Vaccines from both manufacturers, regardless which vaccine was given first.

### Examples:

**Vaccination history:** 1 dose of Pfizer-BioNTech and 1 dose of Moderna COVID-19 vaccines.



2. Children who have a birthday before completing the primary series

- Vaccine product and dosage (amount of vaccine given) is determined by the recipient's age.
- CDC recommends administering the age-appropriate product based on the child's age the day the vaccine will be administered – even if the series was started with a vaccine with younger age indications.
- If a dose(s) of the vaccine product indicated for the younger age group is administered, count the dose(s). Revaccination is not indicated. It is NOT considered a vaccine administration error.
- For detailed guidance see:
  - Pfizer-BioNTech COVID-19 Vaccine: For Children who Transition from a Younger to Older Age Group ([www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf](http://www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf))
  - Moderna COVID-19 Vaccine: For Children who Transition from a Younger to Older Age Group ([www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf](http://www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf))

# COVID-19 Vaccine

Interim COVID-19 Immunization Schedule  
for 6 Months of Age and Older



**Table 3. COVID-19 Vaccine Products Summary**

Product <sup>††</sup>	Age Indications <sup>‡‡</sup>	Diluent	Dosage (amount injected)	
<b>Type: mRNA vaccine</b>				
<b>Moderna</b> (Blue vial cap with magenta-bordered label)	6 months through 5 years	NONE	Any dose in the primary series. Booster doses are not recommended for this age group.	0.25 mL
<b>Moderna</b> (Blue vial cap with purple-bordered label)	6 through 11 years	NONE	Any dose in the primary series.	0.5 mL
	18 years and older	NONE	Booster dose only.	0.5 mL
<b>Moderna</b> (Red vial cap with blue-bordered label)	12 years and older	NONE	Any dose in the primary series.	0.5 mL
	18 years and older	NONE	Any dose in the primary series.	0.5 mL
			Booster dose	0.25 mL
<b>Pfizer-BioNTech</b> (Maroon vial cap with maroon-bordered label)	6 months through 4 years	2.2 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series. Booster doses are not recommended for this age group.	0.2 mL
<b>Pfizer-BioNTech</b> (Orange vial cap with orange-bordered label)	5 through 11 years	1.3 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series and booster doses.	0.2 mL
<b>Pfizer-BioNTech</b> (Purple vial cap with a purple-bordered label)	12 years and older	1.8 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series and booster doses.	0.3 mL
<b>Pfizer-BioNTech</b> (Gray vial cap with a gray-bordered label)	12 years and older	NONE	Any dose in the primary series and booster doses.	0.3 mL
Product	Age Indications	Diluent	Dosage (amount injected)	
<b>Type: Viral Vector Vaccine</b>				
<b>Janssen<sup>§§</sup></b> (Blue Cap)	18 years and older	NONE	Primary and booster dose.	0.5 mL

†† Complete the primary series using the same product. Every effort should be made to determine which vaccine product was received as the first dose. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.

‡‡ Administer the appropriate vaccine product based on the recipient's age and the vaccine product's age indications.

§§ An age-appropriate mRNA COVID-19 vaccine is preferred over the Janssen COVID-19 Vaccine for all vaccine doses for all vaccine-eligible people 18 years of age and older. Janssen COVID-19 vaccine should only be used in limited situations. An mRNA vaccine must be used for the 2nd booster dose. See: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html)

## CDC Resources

CDC COVID-19 vaccine clinical training and materials at: [www.cdc.gov/vaccines/covid-19/info-by-product/index.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html)

CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series)

CDC Vaccine administration clinical materials at: [www.cdc.gov/vaccines/hcp/admin/resource-library.html](https://www.cdc.gov/vaccines/hcp/admin/resource-library.html)

CDC Vaccine Storage and Handling Toolkit at: [www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html](https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html)